Benitec Biopharma Ltd is active in the healthcare domain. The company is engaged in commercialization of its Intellectual Property, It focusses on development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid directed ribonucleic acid interference.